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ABSTRACT
Objectives To estimate the impact of the COVID-19 
pandemic on cancer care services and overall (direct and 
indirect) excess deaths in people with cancer.
Methods We employed near real- time weekly data 
on cancer care to determine the adverse effect of the 
pandemic on cancer services. We also used these data, 
together with national death registrations until June 2020 
to model deaths, in excess of background (pre- COVID-19) 
mortality, in people with cancer. Background mortality 
risks for 24 cancers with and without COVID-19- relevant 
comorbidities were obtained from population- based 
primary care cohort (Clinical Practice Research Datalink) 
on 3 862 012 adults in England.
Results Declines in urgent referrals (median=−70.4%) 
and chemotherapy attendances (median=−41.5%) to a 
nadir (lowest point) in the pandemic were observed. By 
31 May, these declines have only partially recovered; 
urgent referrals (median=−44.5%) and chemotherapy 
attendances (median=−31.2%). There were short- term 
excess death registrations for cancer (without COVID-19), 
with peak relative risk (RR) of 1.17 at week ending on 3 
April. The peak RR for all- cause deaths was 2.1 from week 
ending on 17 April. Based on these findings and recent 
literature, we modelled 40% and 80% of cancer patients 
being affected by the pandemic in the long- term. At 40% 
affected, we estimated 1- year total (direct and indirect) 
excess deaths in people with cancer as between 7165 and 
17 910, using RRs of 1.2 and 1.5, respectively, where 78% 
of excess deaths occured in patients with ≥1 comorbidity.
Conclusions Dramatic reductions were detected in the 
demand for, and supply of, cancer services which have 
not fully recovered with lockdown easing. These may 
contribute, over a 1- year time horizon, to substantial 
excess mortality among people with cancer and 
multimorbidity. It is urgent to understand how the recovery 
of general practitioner, oncology and other hospital 
services might best mitigate these long- term excess 
mortality risks.
Strengths and limitations of this study
 ► This is the first study that used hospital data and a 
predictive model to dissect and quantify the adverse 
impact on mortality of the pandemic on patients with 
cancer and multimorbidity.
 ► This study used the breadth of longitudinal infor-
mation in primary care records from the Clinical 
Practice Research Datalink to generate background 
(pre- COVID-19) mortality estimates for patients with 
cancer.
 ► This study generated 1- year mortality estimates for 
24 cancer types and evaluated the extent by which 
multimorbidity influences mortality risk in patients 
with cancer. We considered 15 comorbidity clusters, 
which include 40 non- malignant comorbidities de-
fined by the Public Health England as associated 
with severe and fatal COVID-19 infection.
 ► This study modelled excess deaths using infor-
mation on background mortality risk and plausible 
relative risk estimates obtained from the Office for 
National Statistics and other published studies.
 ► A limitation of this study is the use of primary care 
health records which may have missed cases of 
cancer resulting in more conservative estimations of 
excess deaths.
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INTRODUCTION
The COVID-19 pandemic may cause additional (excess) 
deaths due to both the direct effects of infection and the 
indirect effects that result from the repurposing of health 
services designed to address the pandemic.1 People with 
cancer are at increased risk of contracting and dying 
from SARS- CoV-2 infection.2 3 Optimal cancer care must 
balance protecting patients from SARS- CoV-2 infection 
with the need for continued access to early diagnosis 
and delivery of optimal treatment.4 5 Professional cancer 
associations internationally have recommended reducing 
systemic anticancer treatment, surgery and risk- adapted 
radiotherapy.6 In June 2020, the National Health Service 
(NHS) released statistics for April 2020, indicating that 
referrals to a consultant for urgent diagnosis of cancer 
had fallen by 60%.7 Some cancer surgical procedures 
have been postponed and cancer screening programmes 
paused.8–13
However, COVID-19- induced healthcare service recon-
figuration and recovery have, to date, not been informed 
by the near real- time hospital data quantifying the extent 
of disruption for patients with cancer resulting from this 
service reconfiguration, nor its impact on excess deaths 
in people with cancer. A previous study has employed 
literature- based estimates to model the impact of potential 
diagnostic delays in colorectal cancer during the COVID-19 
pandemic.14 15 Short- term (30 days) death in people with 
cancer and COVID-19 is importantly driven by (treatable) 
comorbidities such as hypertension and cardiovascular 
disease.16 Public Health England (PHE) has identified 
patients with these and a wide range of other non- malignant 
conditions at greater risk of developing severe illness from 
SARS- CoV-2 exposure,17 18 while multimorbidity in cancer is 
an increasing clinical concern.19 20 For general practitioners 
and oncologists, evidence is required on the pan- cancer esti-
mation of mortality risks according to type and number of 
comorbid conditions. Such evidence may inform individual 
decisions about physical isolation and shielding, as well as 
the need to ensure that patients access specialist cancer care 
and seek preventive care for non- malignant comorbidities.
Our objectives were: (1) to quantify changes in cancer 
care, reporting near real- time weekly data (to June 2020) 
for urgent referral (for early diagnosis of cancer) and 
chemotherapy attendance (for treatment of cancer); (2) to 
quantify short- term direct and indirect excess deaths using 
near real- time weekly death registrations from the Office 
for National Statistics (ONS); (3) to estimate the number 
of annual direct (COVID-19) and indirect excess deaths 
using population- based 1- year Kaplan- Meier mortality esti-
mates for 24 cancer types and (4) to determine the extent 
by which multimorbidity contributes to these excess deaths.
METHODS
Weekly near real-time hospital data
To estimate the extent to which changes in cancer services 
during different phases of the pandemic (pre lock-
down, lockdown, post lockdown easing) have impacted 
on cancer care delivery, we sought weekly information 
for urgent cancer referrals for early diagnosis (‘2- week 
wait’ (2WW)), an indicator of both patient demand 
and health service supply, that is, how well the service is 
ensuring that individuals with suspicious symptoms are 
rapidly prioritised to the diagnostic cancer pathway and 
chemotherapy attendances (an indicator of supply and 
a proxy for possible adverse effects of the pandemic on 
the cancer treatment pathway). We employed the UK’s 
Health Data Research Hub for Cancer (DATA- CAN)21 
to approach eight hospital trusts (in Leeds, London and 
Northern Ireland) and sought data from January 2019 to 
June 2020 to control for seasonal changes. Each hospital 
trust rapidly provided the requested data and permission 
to share these data in the public domain. We estimated 
the per cent change in weekly activity compared with the 
mean activity in 2019.
Weekly near real-time death registration data
To estimate direct (among those infected) and indirect 
impact of the COVID-19 pandemic on deaths, we sought 
weekly counts of deaths in England and Wales from the 
Office for National Statistics (ONS), with causes classified 
by the ONS as COVID-19 deaths, non- COVID-19 deaths 
excluding cancer, and cancer deaths.
Study population: primary care population-based cohort
To estimate pre- COVID-19 incidence and mortality in 
individuals with cancer, we used population- based elec-
tronic health records in England from primary care data 
from the Clinical Practice Research Datalink (CPRD) 
linked to the ONS death registration. We used this primary 
care data source because of the extensive information on 
comorbidities (which may be lacking in cancer registry 
data). The study population was 3 862 012 adults aged ≥30 
years, registered with a general practice from 1 January 
1997 to 1 January 2017, with at least 1 year of follow- up 
data. CPRD data are representative of the English popula-
tion in terms of age, sex, mortality and ethnicity,22–24 with 
extensive evidence of validity.25 This study was performed 
as part of the CALIBER program (https://www. ucl. ac. uk/ 
health- informatics/ caliber). CALIBER is an open- access 
research resource consisting of information, tools and 
phenotyping algorithms available through the CALIBER 
portal (https:// caliberresearch. org/ portal).26 27
Open-access definitions of disease using electronic health 
records
We defined non- fatal incident cases (as alive for at least 
30 days following cancer diagnosis) and prevalent cases of 
cancer across 24 primary cancer sites according to previously 
validated CALIBER electronic health record phenotypes. 
Incident cancers were defined as new cancer diagnoses 
after the study entry into CPRD (baseline). Prevalent 
cancers were defined as cancer diagnoses recorded at any 
time prior to baseline. The cancers included: biliary tract, 
bladder, bone, brain, breast, cervix, colorectal, Hodgkin’s 
lymphoma, kidney, leukaemia, liver, lung, melanoma, 
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multiple myeloma, non- Hodgkin’s lymphoma, oesoph-
agus, oropharynx, ovary, pancreas, prostate, stomach, testis, 
thyroid and uterus.28 Phenotype definitions of cancers and 
COVID-19- relevant comorbidities are available at https:// 
caliberresearch. org/ portal and have previously been vali-
dated.29–32 Phenotypes were generated from hospital and 
primary care information recorded in primary care, using 
Read Clinical Terminology (V.2).
Comorbidities relevant to COVID-19
We examined 15 comorbidity clusters, which include 40 
non- malignant comorbidities defined by PHE as associ-
ated with severe and fatal COVID-19 infection.17 18 We 
separately estimated the proportion of patients with each 
comorbidity at study entry (prevalent cancers), and at the 
date of the first diagnosis of incident cancer. The PHE 
list included chronic respiratory disease, chronic heart 
disease, immunocompromised individuals, HIV, use of 
corticosteroids, obesity, diabetes, chronic kidney disease, 
chronic liver disease, chronic neurological disorders and 
splenic disorders. A full list of the conditions we examined 
and their definitions are provided in online supplemental 
methods.
Estimating incidence rates and 1-year mortality
We estimated incidence rates per 100 000 person- year and 
1- year mortality in our study population. Estimated inci-
dence rates for the number of new cancers by cancer site 
were compared with those for the UK from the Interna-
tional Agency for Research on Cancer and were found to be 
representative. We estimated baseline 1- year mortality risk 
following cancer diagnosis for both incident and prevalent 
cancers using Kaplan- Meier analyses stratified by cancer 
sites and number of (non- cancer) comorbid conditions (0, 
1, 2 and 3+). We used the most recent 5 years of data (2012–
2016) to estimate 1- year mortality.
Estimating 1-year direct excess deaths
Excess deaths were estimated by applying relative risks (RRs) 
to the background 1- year mortality risk. Direct excess deaths 
(due to or with COVID-19) were modelled using the range of 
RRs (1.2, 1.5 and 2.0) previously reported in studies of cancer 
and COVID-19 deaths.3 33 We applied these RRs to 10% of the 
population (the directly ‘infected’), based on recent SARS 
CoV-2 seroprevalence estimates in the UK34 35 and other coun-
tries.36 37 Although the infection rate will change depending 
on the phase of the pandemic, we assumed an infection rate 
over 1 year in line with the first wave of the pandemic.
Figure 1 Weekly hospital data (January 2019–June 2020) on changes in urgent referrals and chemotherapy clinic attendance 
from eight hospitals in the UK mapped to phases of the pandemic. Weekly changes from January 2020 to June 2020 were 
mapped to phases of the pandemic. Weekly values were plotted as percentage increase or decrease relative to the 2019 
average. The data for Northern Ireland include five health and social care trusts (HSCs) that cover all health service provisions 
in Northern Ireland: Belfast HSC, Northern HSC, South Eastern HSC, Southern HSC and Western HSC. Vertical dotted lines 
indicate the Christmas bank holiday.
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Estimating 1-year total (direct and indirect) excess deaths
Indirect excess deaths (due to pandemic- induced 
health service reconfiguration) were estimated by 
applying RRs for excess cancer deaths observed using 
ONS data, by taking the number of weekly cancer 
deaths from January 2020 divided by the weekly 
average over the last 5 years. We assumed that the 
effects of service change may not translate to an 
immediate increase in excess deaths. We have applied 
the RRs of 1.2, 1.5 and 2 to 40% (10% infected, 30% 
affected) and 80% (10% infected, 70% affected) of 
the population and modelled excess deaths over a 
12- month period to capture medium- term effects. 
We chose this range of indirectly ‘affected’ popula-
tion based on our real- time estimates of the degree of 
perturbation in cancer care during the pandemic and 
patient reports that clinical care had been cancelled 
during the pandemic for 53%–70% of patients with 
cancer or other conditions.38
To project the study estimates of excess deaths to 
the whole English population, we employed the 2018 
population estimate, where the number of deaths is 
scaled up to a population of 35 407 313 individuals 
aged 30 and above.39 All analyses were performed 
using R (V.3.4.3).
RESULTS
Near real-time data on cancer care
Evaluating data from 291 792 people with suspected 
cancer and 150 636 patients with cancer attending for 
chemotherapy from January 2019 to June 2020, we 
initially characterised the pre pandemic basal level of 
activity (2019 average), including seasonal variations 
(figure 1). Using the date of the 50th patient diagnosed 
with COVID-19 as the starting point of the pandemic, 
we observed that urgent referrals fell by 70.4% (range: 
−68.7% to −84.3%), while chemotherapy attendances 
declined by 41.5% (range: −26.3% to −63.4%) (figure 1). 
To highlight these adverse impacts, we provided these data 
to chief medical officers in all four nations of the UK and 
the national director for cancer (England). We have also 
continued to provide regular updates of this intelligence 
to the Scientific Advisory Group for Emergencies. Since 
the NHS letter on 29 April 2020 restarting cancer and 
other services,40 and since easing of lockdown (11 May 
2020), there has been evidence of recovery for the urgent 
2WW referrals (−55.4% to −40.0%; median=−44.5%), 
and chemotherapy attendances (−37.1% to 3.9%; 
median=−31.2%) (figure 1).
Near real-time data on cancer, COVID-19 and other deaths
There were 1307 excess cancer deaths from 13 March 
to 15 May 2020 compared with the 5- year average based 
on weekly registration of deaths for England and Wales 
(figure 2A). We found an excess in cancer deaths with 
a peak in the week ending on 3 April 2020 with an RR 
of 1.17 (figure 2B). There were 41105 COVID-19 deaths 
until 15 May 2020. For non- COVID-19 deaths (excluding 
cancers), we found that the peak occurred with an RR of 
1.37 on 24 April 2020. The peak RR for all- cause deaths 
was 2.1, from the week ending 17 April 2020.
Estimations on direct excess deaths by cancer site over 1 year
We estimated direct excess COVID-19 deaths based on a 
SARS CoV-2 infection rate of 10% and background 1- year 
mortality risks (figure 3A). For both incident and preva-
lent cancers combined, we estimated 1790, 4479 and 8957 
direct excess deaths at RRs of 1.2, 1.5 and 2.0, respectively 
(figure 3B). Incidence rates for 24 cancer types were 
shown in online supplemental figure S1. Online supple-
mental figures S2 and S3 show the separate direct excess 
death estimates for incident and prevalent cancers.
Estimations of total (direct and indirect) excess deaths by 
cancer site over a 1 year
When applying RRs of 1.2 or 1.5 to 40% (10% infected, 
30% affected) of the population of people with cancer 
(both incident and prevalent cancers), we estimated 7165 
and 17 910 total excess deaths, respectively (figure 3B). 
When applying these RRs to 80% (10% infected, 70% 
Figure 2 Office for National Statistics data on weekly 
registrations of deaths in the England and Wales from 3 
January 2020 to 15 May 2020. (A) Upper panel indicates the 
number of weekly deaths. (B) Lower panel indicates weekly 
changes in relative risk estimates calculated by comparing 
the current weekly deaths to 5- year weekly averages. Dates 
indicate week ending on a particular date.
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affected) of the population of people with cancer, we esti-
mated 14 326 and 35 817 total excess deaths, respectively 
(figure 3B). Online supplemental figures S2 and S3 show 
the separate total excess death estimates for incident and 
prevalent cancers.
Comorbidities relevant to COVID-19 risk: prevalence and 
association with 1-year mortality
Comorbidities were common in people with incident 
cancer: hypertension (83313 (41.9%)), cardiovascular 
disease (55742 (28.0%)), chronic kidney disease (31935 
(16.0%)), obesity (19589 (9.8%)), type 2 diabetes (18957 
(9.5%)) and chronic obstructive pulmonary disease 
(COPD) (18373 (9.2%)) (online supplemental figure 
S4). Similar patterns were seen in prevalent cancers 
(online supplemental figure S5). Multimorbidity (≥1 
comorbidity) was associated with a higher 1- year mortality 
(online supplemental figure S6) for incident cancers and 
(online supplemental figure S7) for prevalent cancers. For 
example, for incident colorectal cancer, 1- year mortality 
for 0, 1, 2 and 3+ comorbidities was 13.8%, 17.3%, 23.6% 
and 30.2%, respectively (online supplemental figure S6).
Estimations of total (direct and indirect) excess deaths by 
cancer site and number of comorbidities over a 1-year period
To ascertain the influence of multimorbidity on total 
excess deaths, we provide estimates based on 40% (10% 
infected, 30% affected). For both incident and prevalent 
cancers, 78% of the predicted excess deaths occur in 
people with 1+ comorbidity. For example, at RR of 1.2, 
there are 5622 excess deaths in those with 1+ comorbidity 
compared with 1567 in those with no comorbidities (total 
7189) (figure 4). Even though the size of patient group 
in 0, 1, 2 and 3+ comorbidities declines (49.8%, 24.7%, 
15.0% and 10.6%, respectively), the absolute numbers 
of excess deaths in each comorbidity group are similar, 
suggesting that patients with comorbidities contribute to 
a large proportion of excess deaths compared with those 
without non- cancer comorbidities. For example, at RR of 
1.5, the numbers of total excess deaths for both incident 
and prevalent cancers were 3922, 4993, 4526 and 4542 
in individuals with 0, 1, 2 and 3+ non- cancer comorbidi-
ties, respectively (figure 4). The findings for incident and 
prevalent cases are presented separately in online supple-
mental figures S8 and S9.
We share the underlying study estimates from this paper 
(online supplemental data) and provide an open- access 
tool for researchers to interact with the model (https:// 
pasea. shinyapps. io/ cancer_ covid_ app/).
DISCUSSION
Statement of principal findings
To our knowledge, this is the first study with near real- 
time evidence of COVID-19’s negative impact on cancer 
services at different phases of the pandemic, its potential 
to lead to significant excess deaths in people with cancer 
and the substantial role that comorbidities may play in 
these excess deaths.
Figure 3 Estimated total (direct and indirect) excess deaths by cancer site over a 1- year period. (A) 1- year mortality for 
incident and prevalent cancers. The whiskers are 95% CIs. (B) Total excess deaths were scaled up to the population of 
England aged 30+ consisting of 35 million individuals using England mortality estimates for both incident and prevalent cancers 
combined. We estimated direct excess deaths at a 10% infection rate. We estimated total (direct and indirect) excess deaths for 
40% (10% infected, 30% affected) and 80% (10% infected, 70% affected) of the population.
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Changes in cancer care at different phases of pandemic
We delineate both the nadir and the incomplete recovery 
of the UK cancer services that have resulted from the 
COVID-19 pandemic. We observed profound declines in 
urgent 2WW referrals for early cancer diagnosis, which 
have not returned to pre- COVID-19 levels. These may 
reflect patients' deciding not to seek care due to the 
perceived risk of infection, but may also be in part due 
to difficulty in securing appointments due to repriori-
tised health systems.19 An unintended consequence of 
this reprioritisation may be excess deaths due to delayed 
diagnoses, increased emergency presentations, more 
advanced stage at presentation and changes in care path-
ways that adversely affect outcomes. We also observed 
large declines in chemotherapy attendance, presumably 
reflecting capacity/resources being redirected to care for 
infected patients (eg, to intensive care) and the desire of 
clinicians and patients to minimise the risks of COVID-19 
for susceptible patients with cancer.10
Direct (COVID-19) excess deaths
It is important to note that our model estimates deaths 
additional to those that would be expected (without 
COVID-19) in people with cancer. At an RR of 2, we esti-
mate about 9000 direct COVID-19 excess deaths in 1 year 
in people with cancer but acknowledge there is uncer-
tainty in this estimate. There is increasing concern that 
those discharged from hospital with COVID-19 may have 
long- term (including fatal) sequelae.
Total (direct and indirect) excess deaths
Based on our observations regarding the adverse effects 
of cancer service reprioritisation, we consider a propor-
tion affected by the pandemic of 40% plausible, if 
perhaps somewhat conservative. But, given that adverse 
effects could be more profound (our 2WW referrals 
data, for example, would suggest this), we present excess 
deaths for a range of both 40% and 80%. Adding credi-
bility to our estimates, in a survey in April 2020 of 17 000 
UK adults, 56% of patients with cancer reported that the 
NHS had cancelled their treatment.38 Overall, we conser-
vatively estimate, at RR of 1.5, that 17 910 total excess 
deaths for 1 year will occur in patients with cancer, but this 
could rise to 35 817. We note the degree of uncertainty 
in the observed RR at different points in the pandemic. 
Patients affected by changes in cancer services in March–
June 2020 may not necessarily directly contribute to an 
increase in excess indirect deaths in these 4 months, as 
the effects on health and mortality outcomes are more 
likely to occur in a longer time frame.
Importance of multimorbidity
We demonstrate that the majority (78%) of excess deaths in 
people with cancer during the COVID-19 pandemic occur 
Figure 4 Total (direct and indirect) excess deaths for both incident and prevalent cancers by cancer site and number of 
comorbidities over a 1- year period. Stacked bar chart indicates the proportion of individuals with 0, 1, 2 and 3+ comorbidities 
by cancer site. We estimated total excess deaths for 40% (10% infected, 30% affected) of the population. Total excess deaths 
were scaled up to the population of England aged 30+ consisting of 35 million individuals using England mortality estimates for 
both incident and prevalent cancers combined.
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in people with at least one comorbidity. While many of these 
comorbidities are treatable, services for these conditions 
have also been affected by the pandemic. For example, 
65% of patients with hypertension and 70% of patients 
with diabetes reported that the NHS had recently cancelled 
their care, as captured in the same April 2020 survey noted 
above.38 Importantly, the pandemic prompts new questions 
about which patients with cancer are most vulnerable and 
how best to mitigate an individual’s personal risk.
Strengths of this study
There are three major strengths of this study. First, the 
acquisition and deployment of near real- time data to 
signal the significant adverse impact of the COVID-19 
pandemic on cancer services and how this has profound 
implications for cancer diagnostic and treatment path-
ways. These data were also used to inform and enhance 
our existing model that estimates excess mortality due to 
the pandemic. Second, we provide a pan- cancer comor-
bidity atlas using a population- based 3.8 million primary 
care cohort to underpin estimates of the additional 
adverse effect of multimorbidity in patients with cancer; 
cancer registry data tend to lack this more comprehen-
sive information. Third, we provide separate estimates of 
excess deaths for prevalent cancers and incident (newly 
diagnosed) cancers, because these represent different 
patterns of risk, treatment priorities and roles of general 
practitioner and oncologist.
Weaknesses of this study
Our model has important limitations. First, there is a lack 
in the literature of studies on clinical cohorts of patients 
with cancer investigating all- cause mortality rates in those 
with and without infection; such studies are needed in 
order to obtain better estimates of the direct effects of 
the pandemic. Second, the primary care health records 
we used may have missed some cases of cancer and thus 
underestimated incidence.41 If so, our estimates of excess 
deaths may be conservative. The NHS has national linked 
hospital admissions and cancer registration data with 
information on stage and details of surgical, chemother-
apeutic and radiotherapy treatment of cancer. However, 
information governance for such data can take months to 
secure, making data- enabled research and time- sensitive 
responsive service improvement difficult. Third, we did 
not have access to data on children. Fourth, we only have 
access to empirical cancer service change data from eight 
hospitals in the UK. While the data may be a representa-
tive sample of the UK population, and patterns of decline 
in service change is corroborated in another study,42 
more widespread access to other trusts may be beneficial 
to ascertain national and regional effects.
Implications for clinicians and policymakers
Our study may inform decision- making at three levels. 
First, from a healthcare policy and healthcare implemen-
tation perspective, it is clear that the NHS cannot simply 
be ‘switched on’ again at full capacity for hospital or 
primary care services as there will be a significant backlog 
of untreated patients, with waiting lists predicted to 
expand to 10 million patients. Data published on 13 June 
2020 indicate ~1 00 000 ‘missing’ cancer referrals in April 
2020 alone.7 More granular weekly intelligence from the 
centres contributing data to this study suggests that this 
negative impact will continue for at least 6–9 months, 
placing many more patients at risk.
Second, there are currently no accessible national 
systems available for near real- time data on care and 
outcomes of patients with cancer. Our study suggests that 
we should expand our near real- time data approach across 
the UK to collect actionable information on (1) death 
certification—in particular distinguishing the contribu-
tion of cancer, comorbid conditions and COVID-19 to 
death; (2) cancer health services activity data, to monitor 
how changes at each phase of the pandemic (including 
clearing backlogs for under referral, under diagnosis and 
under treatment) might influence future health outcomes 
and (3) treatment services data for non- malignant comor-
bidities of patients with cancer, such as cardiovascular 
disease, diabetes and hypertension.
Third, with knowledge of mortality risk based on type 
of cancer, age and comorbidities that we provide in an 
online format (https:// pasea. shinyapps. io/ cancer_ 
covid_ app/), supplemented with local knowledge of 
health service resilience, we propose that weekly indi-
cators and warnings for vulnerable patients with cancer 
with multimorbidity could be provided. Using this intel-
ligence, treatment prioritisation as we resume cancer 
services could be enhanced by patient- specific risk/
benefit assessments, which include multimorbidity, partic-
ularly in situations where treatment provision outweighs 
non- treatment/safety issues related to COVID-19.19
Unanswered questions and future research
There are important areas for further research. First, 
there is a need for long- term (1–5 years) monitoring 
of the extent to which patients with cancer experience 
excess mortality due to the pandemic. We chose a 1- year 
time horizon, because the adverse consequences on 
health are likely to extend beyond the initial wave of the 
pandemic. But its impact on excess mortality in patients 
with cancer, particularly those whose diagnosis/treatment 
is delayed, may take years to understand. The specific 
impact of paused cancer screening, particularly for breast 
and colorectal cancer, may be profound. The social and 
psychological consequences of physical distancing on 
mortality may also be particularly important in cancer,43 44 
while international studies across 75 countries signpost 
how unemployment negatively impacts mortality in 
patients with cancer.45 Hence, the socioeconomic effects 
of the current pandemic are likely to last for a consid-
erable period beyond 1 year.46 As new empirical data 
become available on heath service, social/psychological 
and economic changes, our model can better specify the 
proportion and type of patients with cancer thus affected 
and look to develop appropriate mitigation strategies.
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CONCLUSION
We mobilised usually inaccessible near real- time hospital 
data to quantify the immediate adverse impacts of the 
COVID-19 pandemic on cancer services, on people who 
may demonstrate symptoms of cancer and on patients 
who are being treated for cancer. The marked reduc-
tions observed in the demand for, and supply of, cancer 
services have only partially recovered with lockdown 
easing. Such perturbations in cancer care may contribute, 
over a 1- year time horizon, to substantial excess mortality 
among people with cancer and multimorbidity. There is 
an urgent need to better understand and mitigate these 
excess mortality risks, some of which may be revealed only 
over the longer term.
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